Business Description
Monopar Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US61023L1089
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.84 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2.5 | |||||
3-Year EPS without NRI Growth Rate | -1.1 | |||||
3-Year FCF Growth Rate | -10.2 | |||||
3-Year Book Growth Rate | -35.1 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.22 | |||||
9-Day RSI | 39.36 | |||||
14-Day RSI | 41.83 | |||||
6-1 Month Momentum % | 144.79 | |||||
12-1 Month Momentum % | -17.54 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.21 | |||||
Quick Ratio | 6.21 | |||||
Cash Ratio | 6.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.2 | |||||
Shareholder Yield % | -31.35 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -104.35 | |||||
ROA % | -80.91 | |||||
ROIC % | -21700 | |||||
ROC (Joel Greenblatt) % | -21700 | |||||
ROCE % | -110.12 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.89 | |||||
Price-to-Tangible-Book | 1.9 | |||||
EV-to-EBIT | -0.86 | |||||
EV-to-EBITDA | -0.86 | |||||
EV-to-FCF | -0.95 | |||||
Price-to-Net-Current-Asset-Value | 1.9 | |||||
Price-to-Net-Cash | 1.96 | |||||
Earnings Yield (Greenblatt) % | -116.28 | |||||
FCF Yield % | -51.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Monopar Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.481 | ||
Beta | 1.07 | ||
Volatility % | 213.23 | ||
14-Day RSI | 41.83 | ||
14-Day ATR (€) | 0.017353 | ||
20-Day SMA (€) | 0.5625 | ||
12-1 Month Momentum % | -17.54 | ||
52-Week Range (€) | 0.24 - 1.45 | ||
Shares Outstanding (Mil) | 17.48 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Monopar Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Monopar Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Monopar Therapeutics Inc Frequently Asked Questions
What is Monopar Therapeutics Inc(FRA:1IY)'s stock price today?
When is next earnings date of Monopar Therapeutics Inc(FRA:1IY)?
Does Monopar Therapeutics Inc(FRA:1IY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |